On April 23, 2021, leading experts in cancer immunotherapy presented an advanced webinar focused on "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma." This webinar was designed for attendees to be able to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease, among other learning outcomes. The recorded webinar and presentation slides are available below.
Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org